Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CVM
stocks logo

CVM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
--
--
-0.110
-31.25%
Estimates Revision
The market is revising No Change the revenue expectations for CEL-SCI Corporation (CVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -40.04%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-40.04%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for CEL-SCI Corp (CVM.A) is -1.48, compared to its 5-year average forward P/E of -11.52. For a more detailed relative valuation and DCF analysis to assess CEL-SCI Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.52
Current PE
-1.48
Overvalued PE
8.42
Undervalued PE
-31.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.89
Undervalued EV/EBITDA
-11.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
332.17
Current PS
0.00
Overvalued PS
1241.04
Undervalued PS
-576.70
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CVM News & Events

Events Timeline

(ET)
2025-08-27
23:44:20
CEL-SCI Prices 1.11M Share Spot Secondary Offering at $9.00
select
2025-08-27
17:28:06
CEL-SCI reveals common stock offering, amount unspecified
select
2025-08-14 (ET)
2025-08-14
10:47:54
CEL-SCI reports Q3 EPS ($1.36) vs. ($4.18) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
09-19NASDAQ.COM
Emerging Growth Stocks Experience Significant Gains in After-Hours Trading

  • Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.

  • Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.

  • Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.

  • Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.

[object Object]
Preview
4.5
08-28Benzinga
Stock Market Update: Nvidia Weighs on Nasdaq Futures—Attention on Dollar General, Dell, and Best Buy

  • Market Overview: U.S. stock futures showed mixed results following gains from the previous day, with Nvidia Corp. experiencing a decline despite reporting better-than-expected second-quarter results.

  • Nvidia's Performance: Nvidia's stock fell due to lack of guidance on H20 shipments to China and weaker data center revenue, although analysts remain optimistic about its leadership in AI infrastructure.

  • Economic Indicators: The 10-year Treasury bond yield was at 4.23%, with markets anticipating an 87.3% chance of interest rate cuts by the Federal Reserve in September; mortgage applications also saw a slight decline.

  • Stock Movements: Notable stock movements included MongoDB Inc. rising 38% after strong earnings, while Kohl’s Corp. gained 24%. Conversely, CEL-SCI Corp. dropped 30.83% after announcing a public offering.

[object Object]
Preview
9.5
08-28Benzinga
Snowflake Shares Surge 14%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Snowflake Inc. Financial Results: Snowflake's shares surged 14.2% in pre-market trading after reporting second-quarter revenue of $1.14 billion and adjusted earnings of 35 cents per share, both exceeding analyst expectations.

  • Other Gainers in Pre-Market Trading: Several stocks saw significant gains, including Erayak Power Solution Group (up 52.5%), Top KingWin Ltd (up 50.5%), and Telomir Pharmaceuticals (up 43.9%).

  • Notable Losers in Pre-Market Trading: CEL-SCI Corporation experienced a sharp decline of 29.8% following a public offering announcement, while The Cooper Companies and Cognition Therapeutics also reported losses of 14.5% and 14.1%, respectively.

  • NVIDIA's Performance: NVIDIA shares fell 2% despite reporting better-than-expected earnings and projecting third-quarter revenue within the consensus estimate range.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CEL-SCI Corp (CVM) stock price today?

The current price of CVM is 6.29 USD — it has increased 5.54 % in the last trading day.

arrow icon

What is CEL-SCI Corp (CVM)'s business?

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

arrow icon

What is the price predicton of CVM Stock?

Wall Street analysts forecast CVM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CEL-SCI Corp (CVM)'s revenue for the last quarter?

CEL-SCI Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is CEL-SCI Corp (CVM)'s earnings per share (EPS) for the last quarter?

CEL-SCI Corp. EPS for the last quarter amounts to -1.36 USD, decreased -67.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for CEL-SCI Corp (CVM)'s fundamentals?

The market is revising No Change the revenue expectations for CEL-SCI Corporation (CVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -40.04%.
arrow icon

How many employees does CEL-SCI Corp (CVM). have?

CEL-SCI Corp (CVM) has 44 emplpoyees as of December 05 2025.

arrow icon

What is CEL-SCI Corp (CVM) market cap?

Today CVM has the market capitalization of 50.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free